[Viva] Fwd: Highlights from CROI 2021 – HIV update, 24 March 2021

[Flower Power]

Awesome

On Thu., Mar. 25, 2021, 6:29 p.m. Margarite Sanchez, <
margaritesanchez at gmail.com> wrote:

>
>
> ---------- Forwarded message ---------
> From: <bulletins at bulletins.aidsmap.com>
> Date: Wed, Mar 24, 2021 at 10:39 AM
> Subject: Highlights from CROI 2021 – HIV update, 24 March 2021
> To: <margaritesanchez at gmail.com>
>
>
> Having problems reading this email? View it in your browser >>
> <https://www.aidsmap.com/node/34331/preview?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
> <https://www.aidsmap.com?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> <https://www.aidsmap.com/donate?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
>
>
> HIV Update   |   24 March 2021
>
> Contents
>
>    - Highlights from CROI 2021
>    <#m_4482078186194408738_m_5123645374654368631_section-1?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>    - Podcast series: Tell Me About It
>    <#m_4482078186194408738_m_5123645374654368631_section-2?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>    - Editors' picks from other sources
>    <#m_4482078186194408738_m_5123645374654368631_section-3?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>    - Video series: women ageing with HIV
>    <#m_4482078186194408738_m_5123645374654368631_section-4?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
>
> Highlights from CROI 2021
>
> One of the most important HIV conferences of the year, the Conference on
> Retroviruses and Opportunistic Infections (CROI 2021)
> <https://www.aidsmap.com/conference/croi-2021?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> took place earlier this month. We have published almost 30 news articles
> from this year’s conference. As it is hard for anyone to keep up, here is a
> round-up of news particularly relevant for people living with HIV in the UK.
> [image: Karan Bunjean/Shutterstock.com]
> Karan Bunjean/Shutterstock.com
> Injectable treatment
>
> There was a lot of new information presented on injectable medications,
> both for treatment and prevention. Injectable cabotegravir/rilpivirine has
> recently been approved by drug regulators for use as HIV treatment. A study
> confirmed that the injections have similar results, whether taken every
> four weeks or every eight weeks
> <https://www.aidsmap.com/news/mar-2021/every-other-month-injectable-cabotegravir-and-rilpivirine-suppresses-viral-load-two?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>,
> although the eight-week regimen is likely to be less forgiving of late
> doses. Experts discussed the practicalities
> <https://www.aidsmap.com/news/mar-2021/injectable-hiv-medications-must-be-practical-and-affordable-conference-hears?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> of providing injection services and which patients will benefit most from
> them.
> Treatment every six months?
>
> Even longer acting medications are also in development, but at earlier
> stages. A small removable implant may provide the drug islatravir
> <https://www.aidsmap.com/news/mar-2021/reformulated-islatravir-implant-should-provide-prep-over-year?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> over one year at a time, or it could be taken as a monthly tablet. An
> injection of the drug lenacapavir
> <https://www.aidsmap.com/news/mar-2021/hiv-capsid-inhibitor-offers-new-option-people-highly-resistant-hiv?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> may be enough for six months at a time. The two pharmaceutical companies
> developing these products have announced plans to investigate whether they
> are effective in combination with each other.
> Promising results towards a functional cure
>
> A therapeutic vaccine allowed some people with HIV to interrupt treatment
> for at least 22 weeks
> <https://www.aidsmap.com/news/mar-2021/therapeutic-vaccine-shows-potential-hiv-control-treatment-early-study?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> and maintain very low viral load, in an early study with 41 participants.
> Therapeutic vaccines have the aim of improving the immune function of
> someone who already has HIV, rather than of preventing the infection. This
> vaccine was designed using insights from the immune response of ‘elite
> controllers’ (individuals who have controlled HIV for long periods of time
> without needing treatment). Indefinite HIV suppression without
> antiretroviral treatment is likely to require a combination approach, for
> example combining this vaccine with other agents.
> [image: Dan Kosmayer/Shutterstock.com]
> Dan Kosmayer/Shutterstock.com
> Four-days-on, three-days-off
>
> Taking antiretroviral medication four consecutive days each week followed
> by a three-day break maintained viral suppression as well as a daily
> regimen,
> <https://www.aidsmap.com/news/mar-2021/four-days-three-days-treatment-regimen-still-looks-effective-after-two-years?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> according to a French study. Those testing the strategy were adults who had
> already had an undetectable viral load for at least a year, no evidence of
> drug resistance and a CD4 count above 250, taking a variety of different
> antiretroviral regimens. With almost two years of follow-up in the study,
> there was a low rate of virological failure, particularly among people
> using integrase inhibitors.
> Disappointing results for São Paulo patient
>
> A Brazilian man who last summer had no evidence of remaining HIV after
> more than 15 months off antiretroviral therapy once again had detectable
> viral load a few months later, the conference was told.
> <https://www.aidsmap.com/news/mar-2021/sao-paulo-patient-experiences-apparent-viral-rebound-year-and-half-after-stopping-hiv?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> Work is underway to determine whether he experienced viral rebound or
> reinfection.
> COVID-19 outcomes
>
> Researchers continue to explore the impact of COVID-19 on people with HIV.
> While several studies have found that people with HIV have worse outcomes
> than other people, UK research presented at the conference
> <https://www.aidsmap.com/news/mar-2021/underlying-health-conditions-play-major-role-increased-risk-hospitalisation-covid-19?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> found that this was entirely attributable to underlying health conditions
> and greater physical frailty in people with HIV. However, a US study found
> a small but statistically significant increase in the risk of
> hospitalisation for COVID-19, even after controlling for some underlying
> conditions.
> [image: Aleks333/Shutterstock.com]
> aleks333/Shutterstock.com
> Protecting bone health
>
> One of the most commonly used antiretroviral medications, tenofovir
> disoproxil fumarate is associated with small losses of bone mineral density
> in some people, usually during the first year of taking the drug. CROI was
> told about a new strategy to prevent this – a short course of alendronate
> around the time of starting tenofovir-based antiretroviral therapy.
> <https://www.aidsmap.com/news/mar-2021/alendronate-can-prevent-bone-loss-people-starting-hiv-treatment?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> Alendronate is an oral medication that is used for the treatment of
> osteoporosis, is inexpensive and well tolerated.
> Weight gain and TAF
>
> An alternative to tenofovir disoproxil fumarate is tenofovir alafenamide
> (TAF), which does not have the same disadvantages in terms of the bones and
> kidneys. However, three new studies showed that TAF is associated with
> weight gain
> <https://www.aidsmap.com/news/mar-2021/what-are-roles-taf-and-integrase-inhibitors-weight-gain?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>.
> Each study tracked weight changes in people switching HIV treatment. The
> three studies came to different conclusions about the role of dolutegravir
> and other integrase inhibitors in weight gain.
> Mindfulness
>
> Online mindfulness audio lessons can significantly reduce depression,
> anxiety
> <https://www.aidsmap.com/news/mar-2021/depression-anxiety-and-loneliness-can-be-improved-mindfulness-audio-lessons?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> and loneliness in older people with HIV, according to a randomised
> controlled trial conducted during the COVID-19 epidemic in the US.
> Mindfulness involves breathing methods, guided imagery, and other practices
> to relax the body and mind and help reduce stress.
> [image: Fizkes/Shutterstock.com]
> Fizkes/Shutterstock.com
> Morning after pill
>
> Doubling the dose of the emergency contraception pill levonorgestrel
> <https://www.aidsmap.com/news/mar-2021/doubling-dose-emergency-contraception-safe-and-effective-way-overcoming-efavirenz?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> can overcome a drug-drug interaction between it and the anti-HIV medication
> efavirenz. The double dose achieved increases in blood concentrations of
> levonorgestrel, making it more likely to be effective. The strategy was
> found to be safe with no reported side effects.
> Treatment for children and adolescents
>
> Dolutegravir-based treatment was superior to treatment based on efavirenz
> or a boosted protease inhibitor in children and adolescents,
> <https://www.aidsmap.com/news/mar-2021/dolutegravir-superior-standard-care-treatment-children-and-adolescents?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> both as first-line or second-line treatment, a randomised study found. The
> results support current guidelines and the use of dolutegravir-based
> regimens in children and adolescents, allowing the same medications to be
> used by most age groups.
>
>
> Podcast series: Tell Me About It [image: Naomi Sutton and Kate Moyle]
>
> The final episode of our podcast series 'Tell Me About It' is out now.
>
> In this episode, Dr Naomi Sutton from Channel 4's *The Sex Clinic* talks
> to psychosexual therapist and podcaster Kate Moyle. They discuss the roots
> of stigma, from colonialism to the language of STIs and 'clean' vs 'dirty',
> and how different things can be now with HIV treatment, PrEP and knowledge.
>
>    - *Listen to all six episodes on Spotify
>    <https://spoti.fi/3tQIIIF?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>or
>    Apple
>    <https://apple.co/2NiTLtF%20?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>*
>    - *Find out more about the series in our blog*
>    <https://www.aidsmap.com/news/feb-2021/new-podcast-series-tell-me-about-it?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
>
> Editors' picks from other sources
> People living with HIV share their experiences of getting the COVID-19
> vaccine
> <https://www.tht.org.uk/news/people-living-hiv-share-their-experiences-getting-covid-19-vaccine?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> | *Terrence Higgins Trust*
>
> No one has to have the vaccine, but Terrence Higgins Trust (THT) is
> encouraging anyone living with HIV to do so. THT asked a handful of people
> living with HIV about why they booked in for their jab, what they
> considered beforehand and what the experience was like.
> Police must remove and end use of database warning markers for HIV to stop
> HIV stigma, says National AIDS Trust
> <https://www.nat.org.uk/press-release/police-remove-end-database-warning-markers-hiv?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> | *National AIDS Trust*
>
> Warning markers identifying a person as living with HIV must be removed
> and no longer used on police databases. This is the recommendation made in
> National AIDS Trust’s new report *HIV and the police*, which documents
> proactive action taken by police in Merseyside and Avon & Somerset to
> address HIV stigma in the force.
> What is the inner life of Jill Baxter on *It’s a Sin*?
> <https://www.thebody.com/article/jill-baxter-its-a-sin?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> | *TheBody*
>
> True-life women caregivers and activists of the AIDS era in the 1980s talk
> about whether Jill's "angel of mercy" character is realistic.
>
>
> Video series: women ageing with HIV [image: Sophie Strachan]
>
> In the second video from our new series, Sophie Strachan, Director of the
> UK HIV charity Sophia Forum, shares her experiences of the menopause as a
> woman living with HIV.
>
> This video has been produced as part of a collaborative project between
> the Sophia Forum, Positively UK, NAM aidsmap and the Institute for Global
> Health, University College London. The GROWS project, women living with HIV
> Growing Older, Wiser and Stronger, is a holistic modelled programme
> supporting women with their health, wellbeing and social care needs.
>
>    - *Watch the video on aidsmap.com
>    <https://www.aidsmap.com/about-hiv/sophie-strachan-menopause-and-hiv-grows-project?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>*
>    - *Find out more about the menopause in NAM's About HIV page*
>    <https://www.aidsmap.com/about-hiv/menopause-and-hiv?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
> ------------------------------
> Connect with us
> <http://www.facebook.com/pages/NAM-the-HIVAIDS-information-charity/99971718192?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
> <https://twitter.com/aidsmap?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
> <https://www.instagram.com/nam_aidsmap?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
> <https://www.youtube.com/channel/UCpqDe1I_t1oV_j67U0HT2bg?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
> <https://www.aidsmap.com/feeds/latest-hiv-news?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
>
>
> <https://www.aidsmap.com/donate?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
>
>
> NAM is an award-winning, community-based organisation, which works from
> the UK. We deliver reliable and accurate HIV information across the world
> to HIV-positive people and to the professionals who treat, support and care
> for them.
> For more details, please contact NAM
> *T* +44 (0)20 3727 0123
> *E* info at nam.org.uk
> <info at nam.org.uk?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> *W* www.aidsmap.com
> <https://www.aidsmap.com?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> *NAM Publications*
> Palladium House 1-4 Argyll Street, London, W1F 7LD
> Company limited by guarantee.
> Registered in England & Wales, number: 2707596
> Registered charity, number: 1011220
>
> *To unsubscribe please click here
> <https://www.aidsmap.com/unsubscribe/?id=bWFyZ2FyaXRlc2FuY2hlekBnbWFpbC5jb20=&bulletin=14397&language=14408&utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>*
>
> *Privacy Policy*: www.aidsmap.com/about-us/confidentiality
> <http://www.aidsmap.com/about-us/confidentiality?utm_source=hiv+update-english&utm_medium=email&utm_campaign=2021-03-24>
> _______________________________________________
> VIVA mailing list
> VIVA at lists.resist.ca
> https://lists.resist.ca/cgi-bin/mailman/listinfo/viva
>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.resist.ca/pipermail/viva/attachments/20210326/ccc5312b/attachment-0001.htm>